No Data
No Data
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Express News | Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating
Longboard Pharmaceuticals Advances Neurological Treatments
Longboard Pharmaceuticals Reports Q3 EPS (63c), Consensus (58c)
No Data
No Data
101715680 : Give 20 days sure drop
10percents OP : why this is not moving up?